Showing 1427 results
-
Press release /Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
-
Story /Melanoma survivor T.J. Sharpe discusses his personal experience with cancer and the important role caregivers play in a patient’s road to recovery.
-
Story /Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research
-
Story / -
Press release /European Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for…
-
Press release /Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD…
-
Press release /Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
-
Press release /RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4]…
-
Press release /Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…